Physician profile
Daniel Tupper Iseman
NPI 1093777310
$16,733.13
in general payments reported to CMS, 2019-2025
39 companies · $2,723 in 2025
The $2,723 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,702 · 2020: $1,727 · 2021: $2,879 · 2022: $2,270 · 2023: $2,640 · 2024: $2,792 · 2025: $2,723.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,059 · Education: $95.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,059.41 |
| Education | $95.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,676.35 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,502.97 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,381.26 | 2019-2025 | Entyvio, Gattex |
| Qol Medical, LLC | $1,069.91 | 2020-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $1,002.46 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Pfizer INC. | $812.66 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $555.24 | 2019-2024 | Dificid, Zinplava |
| Ardelyx, INC. | $512.63 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $498.82 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $378.54 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $345.21 | 2019-2025 | Rebyota, Clenpiq |
| Ironwood Pharmaceuticals, INC | $336.14 | 2019-2024 | Linzess |
| Celgene Corporation | $317.25 | 2021-2024 | Zeposia |
| Genzyme Corporation | $304.62 | 2022-2025 | |
| Lilly USA, LLC | $269.38 | 2024-2025 | Omvoh |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Iseman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.